Suchergebnisse

This volume explores changing global perspectives in banking of cord blood, mesenchymal, embryonic and induced pluripotent stem cells for clinical use.

Cover -- Title -- Copyright -- Contents -- Introduction Real-life case study -- Chapter 1 What are stem cells? -- Chapter 2 Sources of stem cells -- Chapter 3 The ethical issues -- Chapter 4 The possibilities of stem cell research -- Chapter 5 Legal rulings on stem cell use -- Chapter 6 What does the future hold? -- Timeline -- Glossary -- Further reading -- Index

Cloning, the generation of genetically identical individuals, frequently occurs in plants and in several animal groups. Nowadays cloning is technically reproducible thanks to both embryo splitting and somatic cell nuclear transfer thus playing an important role in zootechnical applications (i.e., to increase transgenic animals for drug production) and in biomedicine (i.e, to produce embryonic stem cells in animal models, cybrids, etc.). The relevant historical advancements of these techniques and the related ethical issues are discussed. A brief review of the formation of a new individual as "a process" clearly leads to the impossibility for the biologist to unambiguously determine at which stage a new individual is first formed. However, the application of the scientific method to this issue produces a communal statement independent from ideological or religious opinion: ontogenetically, the material-energetic process originating and identifying a new individual is coincident with the moment in which the first genetically active copy of his genome is formed. Even the critical production of patient-specific stem cells (therapeutic cloning) it is most likely to be superseded and devoided of any ethical concerns thanks to the technical advancements developed by Shinia Yamanaka on the genetic reprogramming of terminally differentiated nuclei. The production of specific cell types might address the therapy of nearly all the pathologies. Noteworthy, starting April 2009 but actually beginning August 2010, the FDA gave green light to the first trial based on the administration of neuronal cells derived from human embryonic stem cells to 11 patients with severe spinal cord injury. Bio-political topics are briefly frameworked within the elaboration of ethical principles and laws that respect multiple values, which are necessary in multi-ethnic cultures.

While many people believe that scientific research involving stem cells will advance medical knowledge, others argue that the use of embryonic stem cells objectifies or even destroys potential human life. This book explores the legal and political ramifications of the debate

The Spanish National Stem Cell Bank (Banco Nacional de Líneas Celulares, BNLC) was established in 2006 thanks to a change in the legislative framework in Spain. The Law 14/2006 updated the previous Assisted Reproduction Techniques Law (Law 45/2003) allowing the use of the surplus frozen embryos following IVF for research. The BNLC has a network structure with 3 nodes: the Regenerative Medicine Program (IDIBELL), the Principe Felipe Research Center (CIPF) in Valencia and the Andalusian Public Health System Biobank (SSPA Biobank) in Granada. The aim of the BNLC is to guarantee throughout the national territory the availability of human stem cell lines for biomedical research. At present time, there are 40 human embryonic stem cell lines (hESC) and 171 human induced pluripotent stem cell lines (hiPSC) registered in the BNLC. These lines are fully characterized and available in the context of research projects approved by the Technical Committee of the BNLC. ; The National Spanish Stem Cell Bank is supported by the Plataforma de Proteomica, Genotipado y Líneas Celulares (PT1770019/0015) (PRB3), Instituto de Salud Carlos III. ; Sí

The recent data on epigenetic control of differentiation in mesenchymal stem cells to be the background of embryogenesis and regeneration process in organism are considered. Epigenetic control is bases on three intramolecular mechanisms – DNA methylation, structural modification of histone proteins and microRNA active on posttranscription and posttranslation levels. As an example, the issues of stem cell differentiation in the liver are considered.

Stem cell therapy has long been considered a promising mode of treatment for retinal conditions. While human embryonic stem cells (ESCs) have provided the precedent for regenerative medicine, the development of induced pluripotent stem cells (iPSCs) revolutionized this field. iPSCs allow for the development of many types of retinal cells, including those of the retinal pigment epithelium, photoreceptors, and ganglion cells, and can model polygenic diseases such as age-related macular degeneration. Cellular programming and reprogramming technology is especially useful in retinal diseases, as it allows for the study of living cells that have genetic variants that are specific to patients' diseases. Since iPSCs are a self-renewing resource, scientists can experiment with an unlimited number of pluripotent cells to perfect the process of targeted differentiation, transplantation, and more, for personalized medicine. Challenges in the use of stem cells are present from the scientific, ethical, and political realms. These include transplant complications leading to anatomically incorrect placement, concern for tumorigenesis, and incomplete targeting of differentiation leading to contamination by different types of cells. Despite these limitations, human ESCs and iPSCs specific to individual patients can revolutionize the study of retinal disease and may be effective therapies for conditions currently considered incurable.

Proponents describe stem Cell Replacement Therapy and related technologies to be a significant step forward for medicine. However, due to the inherent ethical problems in human Embryonic Stem Cell Research (hESC), it is strictly regulated around the world. The US has passed at the federal and state level, both supportive and restrictive laws over the years. The changing legislative environment at the state and federal levels has created a situation whereby researchers have to choose whether and where to carry out this research. By exploiting the temporal and spatial heterogeneity and legislative shocks, we assess if the affected scientists have voted with their feet, leaving the state or country imposing restrictive rules and whether hESC research has clustered geographically. We find that most of the hESC research is carried out in supportive states, and significant legislative changes have had a minor but noticeable effect on relocation choices. Most importantly, the research has moved to supportive states. This result suggests that several state-level interventions (supportive), which were opposed to federal laws (restrictive), have counteracted each other. © 2021, The Author(s).